Irbesartan and Cardiotoxicity - a phase IV clinical study of FDA data

Summary:

Cardiotoxicity is reported as a side effect among people who take Irbesartan (irbesartan), especially for people who are male, 60+ old, also take Amlodipine, and have Hyperuricaemia.

The phase IV clinical study analyzes which people have Cardiotoxicity when taking Irbesartan. It is created by eHealthMe based on reports of 35,908 people who have side effects when taking Irbesartan from the FDA, and is updated regularly.

What is Irbesartan?

Irbesartan has active ingredients of irbesartan. It is often used in high blood pressure. eHealthMe is studying from 36,414 Irbesartan users. Check the latest studies of Irbesartan.

What is Cardiotoxicity?

Cardiotoxicity (damage to the heart muscle) is found to be associated with 387 drugs and 509 conditions by eHealthMe. Check the latest studies of Cardiotoxicity.

On Jul, 09, 2026

35,908 people reported to have side effects when taking Irbesartan.
Among them, 16 people (0.04%) have Cardiotoxicity.

Among these 16 people:

What is the gender of people who have Cardiotoxicity when taking Irbesartan? *

female: 27.27 %
male: 72.73 %

What is the age of people who have Cardiotoxicity when taking Irbesartan? *

What are other drugs people take besides Irbesartan? *

What are other side effects people have besides Cardiotoxicity? *

Overdose: 14 people, 87.50%
Hypoglycemia (low blood sugar): 5 people, 31.25%
Blood Pressure Systolic Decreased: 4 people, 25.00%
Heart Rate Decreased: 4 people, 25.00%
Hypokalemia (low potassium): 2 people, 12.50%
Ventricular Failure (heart failure): 1 person, 6.25%
Diastolic Dysfunction: 1 person, 6.25%
Abdominal Pain Upper: 1 person, 6.25%
Back Pain: 1 person, 6.25%
Cardiac Failure: 1 person, 6.25%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 1 person, 6.25%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Irbesartan and have Cardiotoxicity?

- Check whether Cardiotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Irbesartan:

Irbesartan (36,414 reports)

Cardiotoxicity treatments and more:

Cardiotoxicity (8,120 reports)

Browse all side effects of Irbesartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiotoxicity:

Cardiotoxicity (387 drugs)

Browse all the conditions that are associated with Cardiotoxicity:

Cardiotoxicity (509 conditions)

Related publications that referenced our studies

Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .
Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on irbesartan (the active ingredients of Irbesartan) and Irbesartan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.